Acumen, JCR Pharmaceuticals enter collaboration, option, license agreement

Acumen (ABOS) Pharmaceuticals announced a collaboration, option and license agreement with JCR Pharmaceuticals to develop an oligomer-targeted Enhanced Brain Delivery therapy for Alzheimer’s disease. While the blood-brain barrier protects the human brain from potentially harmful substances, this protective barrier makes it challenging to deliver therapeutics, especially larger molecules like biologics, into the brain at higher quantities. The combination of sabirnetug or additional, novel, AbetaO-selective antibodies with JCR’s BBB-penetrating technology strengthens Acumen’s portfolio of AbetaO-targeted therapies. The partnership is designed to advance potential next-generation treatment options for people living with Alzheimer’s disease, by targeting the development of products with enhanced efficacy, safety and convenience.